The FDA has approved the combination of enfortumab vedotin (EV) and pembrolizumab for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, marking a major advance in…
Interactive Cancer Care Network (ICCN) strives to provide Community Oncologists with medical education regarding the most up to date drug approvals and treatment landscape changes. Providing insights from national key opinion leaders allows for the opportunity to ask questions relevant to your clinical practice. At this time we offer virtual programs tailoring to the busy schedules of medical providers. We look forward to having you join the ICCN community.